News

Video: Jenniffer Dietrich, Challenge Facility for Civil Society

Jenniffer Dietrich is Technical Officer at the Challenge Facility for Civil Society of the Stop TB Partnership.

Communities are coming together to advocate and improve their own access to health services and increasingly organizing to plan and deliver effective healthcare on a large scale. Though it will never replace or match the national delivery of health, it can and does make a considerable contribution acting synergistically to improve access for marginalized groups, maintaining contact and referral to health services and ultimately creating a highly effective network of health interventions and community health systems.

The Stop TB Partnership’s Challenge Facility for Civil Society (CFCS) targets grass-roots and community-based civil society organizations that seek to help shape policy at local levels by giving a voice to people living with TB and those involved in its prevention, treatment and care. Proposals are selected by an independent selection committee composed of a maximum of 10 representatives from the community affected by TB, NGOs from developing and developed countries, NTP managers, multilateral or technical agencies.

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...